Zevra down on EU snub for rare disease therapy (ZVRA:NASDAQ)
· seekingalpha.com
Zevra Therapeutics (ZVRA) stock plunged after an advisory panel of the EU drug regulator refused to endorse the company's rare disease drug, arimoclomol. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...